MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412897 | Name: Cilobradine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cilobradine is an HCN Channel blocker; an open channel blocker of neuronal Ih and related cardiac If channels.

Chemical Structure

Cilobradine
Cilobradine
CAS# 147541-45-5

Theoretical Analysis

MedKoo Cat#: 412897

Name: Cilobradine

CAS#: 147541-45-5

Chemical Formula: C28H38N2O5

Exact Mass: 482.2781

Molecular Weight: 482.62

Elemental Analysis: C, 69.68; H, 7.94; N, 5.80; O, 16.58

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Cilobradine; UNII-5O1LL04GJ3
IUPAC/Chemical Name
(S)-3-((1-(3,4-dimethoxyphenethyl)piperidin-3-yl)methyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one
InChi Key
OBUFMJDDZTXJPY-NRFANRHFSA-N
InChi Code
InChI=1S/C28H38N2O5/c1-32-24-8-7-20(14-25(24)33-2)9-12-29-11-5-6-21(18-29)19-30-13-10-22-15-26(34-3)27(35-4)16-23(22)17-28(30)31/h7-8,14-16,21H,5-6,9-13,17-19H2,1-4H3/t21-/m0/s1
SMILES Code
COc1c(OC)cc(CCN2CCC[C@@H](C2)CN3CCc4c(CC3=O)cc(OC)c(OC)c4)cc1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 482.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Lu TL, Lu TJ, Wu SN. Inhibitory Effective Perturbations of Cilobradine (DK- AH269), A Blocker of HCN Channels, on the Amplitude and Gating of Both Hyperpolarization-Activated Cation and Delayed-Rectifier Potassium Currents. Int J Mol Sci. 2020 Mar 31;21(7):2416. doi: 10.3390/ijms21072416. PMID: 32244431; PMCID: PMC7177279. 2: Vélez de Mendizábal N, Staab A, Schäfer HG, Trommeshauser D, Döge C, Klüglich M, Roberts J, Trocóniz IF. Joint population pharmacokinetic/pharmacodynamic model for the heart rate effects at rest and at the end of exercise for cilobradine. Pharm Res. 2013 Apr;30(4):1110-22. doi: 10.1007/s11095-012-0947-6. Epub 2012 Dec 11. PMID: 23229858. 3: Tanguay J, Callahan KM, D'Avanzo N. Characterization of drug binding within the HCN1 channel pore. Sci Rep. 2019 Jan 24;9(1):465. doi: 10.1038/s41598-018-37116-2. PMID: 30679654; PMCID: PMC6345760. 4: Van Bogaert PP, Pittoors F. Use-dependent blockade of cardiac pacemaker current (If) by cilobradine and zatebradine. Eur J Pharmacol. 2003 Oct 8;478(2-3):161-71. doi: 10.1016/j.ejphar.2003.08.083. PMID: 14575801. 5: Fliss G, Staab A, Tillmann C, Trommeshauser D, Schaefer HG, Kloft C. Population Pharmacokinetic Data Analysis of Cilobradine, an I f Channel Blocker. Pharm Res. 2008 Feb;25(2):359-68. doi: 10.1007/s11095-007-9351-z. Epub 2007 Jun 21. PMID: 17587152. 6: Stieber J, Wieland K, Stöckl G, Ludwig A, Hofmann F. Bradycardic and proarrhythmic properties of sinus node inhibitors. Mol Pharmacol. 2006 Apr;69(4):1328-37. doi: 10.1124/mol.105.020701. Epub 2005 Dec 30. PMID: 16387796. 7: Hung TY, Huang CW, Wu SN. High ability of zileuton ((±)-1-(1-benzo[b]thien-2-ylethyl)-1-hydroxyurea) to stimulate IK(Ca) but suppress IK(DR) and IK(M) independently of 5-lipoxygenase inhibition. Eur J Pharmacol. 2020 Nov 15;887:173482. doi: 10.1016/j.ejphar.2020.173482. Epub 2020 Aug 12. PMID: 32795513. 8: Maccarone R, Izzizzari G, Gargini C, Cervetto L, Bisti S. The impact of organic inhibitors of the hyperpolarization activated current (Ih) on the electroretinogram (ERG) of rodents. Arch Ital Biol. 2004 Mar;142(2):95-103. PMID: 15248565. 9: Cheng Y, George I, Yi GH, Reiken S, Gu A, Tao YK, Muraskin J, Qin S, He KL, Hay I, Yu K, Oz MC, Burkhoff D, Holmes J, Wang J. Bradycardic therapy improves left ventricular function and remodeling in dogs with coronary embolization- induced chronic heart failure. J Pharmacol Exp Ther. 2007 May;321(2):469-76. doi: 10.1124/jpet.106.118109. Epub 2007 Feb 2. PMID: 17277196. 10: Schmitz-Spanke S, Granetzny A, Stoffels B, Pomblum VJ, Gams E, Schipke JD. Effects of a bradycardic agent on postischemic cardiac recovery in rabbits. J Physiol Pharmacol. 2004 Dec;55(4):705-12. PMID: 15613737.